Skip to content
Menu

Anavex Life Sciences Corp. AVXL

Full chart Compare
Set alert

Price alert · AVXL

All alert types
0.84 USD -0.09 (-9.99%)

As ofNov 16, 2026, 1:37 PM EST

0.8351 Day range 0.95
0.8351 52-week range 5.36
YTD
-76.40%
1 year
-76.92%
Market cap
77.88M
EPS (ttm)
-0.14
Shares out
84.80M
Forward P/E
-17.25
YTD return
-76.40%
1-year return
-76.92%
50-day average
7.73
200-day average
5.65
Enterprise value
593.03M
Volume
1.18M
Avg volume
1.05M
Open
0.94
Previous close
0.9335
Day's range
0.8351 – 0.95
52-week range
0.8351 – 5.36
Beta
0.60
Analysts
Strong Buy
Price target
35.47 (+4121.9%)

5D -0.3164 (-26.81%)

1.00001.2000TueWedThuFriMon0.8636

Key statistics

Price / book
7.10
Free cash flow
-19.06M
Total cash
138.76M
Return on equity
-30.03%
Short % of float
23.96%

Fundamental scorecard

7 of 25 checks passed on AVXL’s reported financials

ValueGrowthProfitabilityHealthDividend

7of 25 checks passed

  • Value 1 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Jun 30, 2026.

Financials — quick view

All financials
AVXL Revenue — quarterly 0
AVXL Net income — quarterly 7.82M
AVXL EPS — quarterly 0.08

Upgrades / downgrades

AVXL analyst upgrades and downgrades
DateFirmActionFromTo
Dec 23, 2024D. Boral CapitalmainBuyBuy
Nov 27, 2024HC Wainwright & Co.reitBuyBuy
Nov 26, 2024D. Boral CapitalmainBuyBuy
Nov 25, 2024D. Boral CapitalmainBuyBuy
Nov 4, 2024HC Wainwright & Co.reitBuyBuy
Oct 31, 2024EF HuttonmainBuyBuy

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
anavex.com

News

Your note

Sign in to keep a note on AVXL — it syncs with the Stock Master app.

Insider holders

AVXL insider holders
InsiderRelationLatest transactionDateShares held
DONHAUSER PETER D.O.DirectorPurchaseJun 13, 20245,000
MISSLING CHRISTOPHER UChief Executive OfficerSaleMar 27, 20241,250,210
THOMAS STEFFEN PHDDirectorPurchaseMay 14, 20245,000

Institution ownership

AVXL institution ownership
Holder% heldSharesValueReported
Blackrock Inc.7.95%6,740,69673.27MSep 29, 2024
Vanguard Group Inc5.59%4,740,17151.53MSep 29, 2024
State Street Corporation3.62%3,065,94733.33MSep 29, 2024
Geode Capital Management, LLC2.22%1,883,19920.47MSep 29, 2024
NWAM LLC1.07%910,4769.90MSep 29, 2024
Two Sigma Investments, LP0.98%830,6249.03MSep 29, 2024

Fund ownership

AVXL fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund2.99%2,534,50027.55MSep 29, 2024
iShares Russell 2000 ETF2.30%1,946,16921.15MOct 30, 2024
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF1.89%1,604,41517.44MSep 29, 2024
Vanguard Extended Market Index Fund1.57%1,331,91814.48MSep 29, 2024
Fidelity Small Cap Index Fund0.88%746,3168.11MAug 30, 2024
iShares Biotechnology ETF0.69%581,9496.33MOct 30, 2024